The identification of inhibitors targeting regulatory subunits of serine/threonine PP1 phosphatases reported by Krzyzosiak et al . is a significant step in expanding the pharmacological regulation of phosphorylation beyond kinases. The selective inhibitor of the R15B phosphatase regulatory subunit, termed Raphin1, protects cells from stress and delays neurodegeneration in a mouse model of Huntington's disease.
Research into the regulation of protein phosphorylation over the last decades has focused on kinases, and the examination of phosphatases has stagnated. Kinase inhibitors have become one of the pharmaceutical companies's favored targets, with at least 48 clinically approved compounds (http://www.kinase-screen. mrc.ac.uk/phosphorylation-ubiquitylationdrug-discovery), and many more are in clinical development (Ferguson and Gray, 2018) . In this issue of Cell, the findings reported by Krzyzosiak et al. (2018) targeting a regulatory subunit of a serine/threonine PP1 phosphatase complex pave the way for new therapeutic approaches to correct aberrant protein phosphorylation.
Screens undertaken some years ago identified two compounds, termed Guanabenz (Tsaytler et al., 2011) and Sephin1 (Das et al., 2015) , that protect cells from otherwise lethal doses of endoplasmic reticulum stress that induces unfolding of proteins. These compounds inhibit a protein phosphatase 1 (PP1) holoenzyme (a complex consisting of the PP1 catalytic subunit and a regulatory subunit termed R15A) that acts to dephosphorylate eIF2a at Ser51 (Harding et al., 2009) , and thus, they exert their stress-protective properties by prolonging the beneficial effects of phosphorylation of eukaryotic translation initiation factor 2 (eIF2a) on Serine 51. Such responses include a rapid slow down of protein synthesis and an increase in the capacity of chaperones and proteosomal machinery to clear misfolded proteins before they accumulate to dangerous levels. Illustrating the importance of this pathway, there are four Ser51 eIF2a kinases that are active in response to different types of stress (Donnelly et al., 2013) ( Figure 1A ).
Cells possess another PP1 regulatory subunit termed R15B, which is 28% identical to R15A, that appears to play a more general role in dephosphorylating eIF2a (Tsaytler et al., 2011 and Das et al., 2015) ( Figure 1A ). Guanabenz and Sephin-1 are selective for the R15A PP1 complex and do not significantly inhibit R15B PP1. Krzyzosiak et al. reasoned that targeting the R15B:PP1 complex instead of R15A could be a better choice to obtain inhibitors that are effective against diverse stresses. This was an ambitious quest, as PP1 holoenzyme complexes had never been targeted previously.
To achieve this, Krzyzosiak and coworkers reconstituted the partial R15A/ PP1 and R15B-PP1 holoenzymes on a surface plasmon resonance sensor chip and undertook a compound binding screen with a small library of 69 derivatives of Ganabenz. This lead to the discovery of the compound termed Raphin1, which binds R15B-PP1 with 30-fold selectivity over the R15A-PP1 complex. When used in cells, Raphin1 increases eIF2a phosphorylation and decreases protein synthesis. These effects are lost following knockout of the R15B subunit, confirming that the mechanism of action of Raphin1 is indeed mediated through R15B. The effects on Raphin1 on eIF2a phosphorylation and protein synthesis are transient, with recovery observed after around 10 hr. Further analysis reveals that this is caused by marked upregulation of the R15A subunit occurring after about 2 hr of Raphin1 administration. More work is needed to establish the mechanism by which cells upregulate R15A following inhibition of R15B.
Raphin1, when administered to mice at doses as low as 2 mg/kg, accumulates in tissues, including brain, at sufficiently high concentrations to inhibit R15B and has no reported adverse effects on the animals. When Raphin1 is administered once per day to a mouse model of Huntington's disease over a 6-week period, it markedly decreases insoluble Huntingtin protein aggregates and significantly delays disease onset. There are currently no treatments that prevent or even delay disease progression of Huntington's and other neurodegenerative disorders caused by abnormal protein misfolding. In future work, it will be vital to further explore whether Raphin1 or other R15B inhibitors have therapeutic benefit for these devastating diseases in humans.
Currently, the only drugs that target a protein phosphatase complex are the macrolide FK506 and its derivativesimmunosuppressive agents developed over 20 years ago. These bind to the immunophilin FKBP12 and suppress activity in the calcineurin (protein phosphatase 3) complex, thereby blocking activation of the transcription factor nuclear factor of activated T cell cytoplasmic (NFATc) in T cells (Rusnak and Mertz, 2000) . To our knowledge, only a single phosphatase inhibitor termed LB100, which targets PP2A, is currently in early-phase clinical trials for treatment of recurrent glioblastoma. Selective allosteric inhibitors of a variety of tyrosine phosphatases, including protein tyrosine phosphatase 1B-obesity and associated co-morbidities (PTP1B), SHP2 (the tyrosine phosphatase produced by the oncogene PTPN11-oncology), and SHP1 (produced by the PTPN6 gene oncology and immune disorders) have been elaborated, but research is still at the preclinical stage (He et al., 2014) .
Drug discovery efforts targeting the catalytic subunits of PP1 had been quickly abandoned in the 1990s, as natural compounds, including microcystin and calyculin A, that inhibited all PP1 holoenzymes were found to be highly toxic (Cohen, 2002) . It was assumed infeasible to target specific PP1 holoenzymes. The work performed by Krzyzosiak et al. provides much-needed ammunition showing that crafting selective inhibitors targeting PP1 holoenzymes is indeed achievable. Raphin-1 binding to R15B induces a conformational change, resulting in it becoming targeted for p97 and proteasome-mediated degradation in vivo (Krzyzosiak et al., 2018) . However, there are other mechanisms of action that could be considered for developing inhibitors of PP1 holoenzymes in future studies, increasing opportunity for success (Figure 1 B) . These include blocking the PP1 regulatory subunit from accessing its physiological substrate or inducing disassembly of regulatory and catalytic subunits. There may also be other functionally critical pockets on certain PP1 holoenzymes that could be exploited ( Figure 1B) . In future work, we would advocate incorporating unbiased quantitative total and phosphoproteomic analyses (that were not utilized in the Krzyzosiak et al. study) into the workflow to better characterize the in vivo specificity of identified PP1 holoenzyme inhibitors.
The Krzyzosiak study represents a major step forward, providing the strongest evidence to date that PP1 holoenzymes are indeed druggable. The research validates R15B as a promising target to slow progression of a range of devastating neurodegenerative conditions. Perhaps the greatest challenge going forward will be to define which PP1 holoenzyme complexes should be targeted to treat specific diseases (Ferreira et al., 2018) , as the physiological roles of the vast majority of these enzymes, of which there are over 200, are unknown. Fundamental mechanistic research in this neglected field of phosphatase biology is urgently needed. Defining the key set of physiological substrates that individual PP1 holoenzymes act upon would significantly contribute to the growing armory of approaches that can be deployed to modulate protein phosphorylation for treatment of disease. (A) Eukaryotic translation initiation factor 2 (eIF2a) is phosphorylated at Ser51 during stress response to slow down translation. Four different kinases (PERK, PKR, CGN2, and HRI) can phosphorylate eIF2a depending on the type of stress. Two different but related protein phosphatase 1 (PP1) holoenzymes (complexes consisting of the PP1 catalytic subunit [PP1c] and a regulatory subunit termed R15A or R15B) counteract these phosphorylations. The newly discovered drug Raphin1 binds selectively to the regulatory subunit R15B, causing a conformational change to the protein structure that ultimately leads to degradation of the subunit, thus inactivating the phosphatase complex. (B) Alternative strategies could be used to target the PP1 holoenzymes (PP1c + R). Inhibitors (I) can be designed (1) to block the binding of the regulatory subunit with the substrate (substrate binding pocket), (2) to block the binding between PP1c and the regulatory subunit (PP1 binding pocket), and (3) to interfere with other essential domains of the regulatory subunit (other functional pocket).
